Table 2.
Demographic characteristics of 29 patients with culture isolation of Clostridium difficile ribotype 002 in Hong Kong
| Case and (strain) no. | Sex/age | Disease status (disease score)a | Underlying disease(s) | Antibiotic therapy 1 week before culture of C. difficile | Days between the identification of C. difficile and admission | Days between the identification of C. difficile and death |
|---|---|---|---|---|---|---|
| 1 (171) | M/89 | Symptomatic (1) | IHD, MDS | Nil | 1b | 330 |
| 2 (196) | F/81 | Symptomatic (2) | CRF, HT | Cefuroxime, levofloxacin | 61 | 302 |
| 3 (213) | M/38 | Symptomatic (3) | Refractory ALL | Meropenem | 7 | 27 |
| 4 (229) | M/14 | Colonization | ALL | Cefoperazone/sulbactam, amikacin | 1 | NA |
| 5 (330) | M/54 | Symptomatic (2) | NPC | Nil | 1b | NA |
| 6 (339) | M/55 | Symptomatic (4) | Liver Tx recipient | Nil | 25 | 131 |
| 7 (341) | M/46 | Symptomatic (1) | AML | Imipenem/cilastatin | 13 | NA |
| 8 (386) | F/48 | Symptomatic (0) | CA of the urethra | Levofloxacin | 4 | 148 |
| 9 (398) | F/91 | Symptomatic (1) | CA of the lung | Amoxicillin/clavulanate | 45 | 14 |
| 10 (408) | M/25 | Colonization | Lymphoma | Meropenem, vancomycin | 27 | NA |
| 11 (412) | M/33 | Colonization | HT, renal Tx recipient | Amoxicillin/clavulanate | 30 | NA |
| 12 (445) | M/93 | Symptomatic (3) | Sick sinus syndrome | Cefuroxime | 7 | 87 |
| 13 (457) | M/59 | Colonization | CRF, DM, HT | Piperacillin/tazobactam, vancomycin | 31 | 142 |
| 14 (570) | M/95 | Symptomatic (1) | CRF, DM, HT | Ciprofloxacin, co-trimoxazole | 61 | 246 |
| 15 (428) | M/86 | Colonization | IHD, parkinsonism | Amoxicillin/clavulanate | 88 | 297 |
| 16 (486) | M/73 | Symptomatic (1) | CA of the lung, IHD | Nil | 13 | NA |
| 17 (476) | F/42 | Colonization | Lymphoma | Nil | 79 | 24 |
| 18 (536) | M/86 | Symptomatic (1) | IHD | Nil | 1b | NA |
| 19 (526) | F/96 | Colonization | CA of the colon, CHF | Amoxicillin/clavulanate | 21 | 114 |
| 20 (531) | M/76 | Colonization | CRF, HT | Levofloxacin | 7 | 291 |
| 21 (538) | F/21 | Colonization | AML | Piperacillin/tazobactam,vancomycin | 4 | 191 |
| 22 (535) | F/96 | Symptomatic (2) | CHF | Nil | 1b | 110 |
| 23 (580) | M/97 | Symptomatic (2) | CHF, dementia | Amoxicillin/clavulanate | 14 | 113 |
| 24 (586) | M/75 | Colonization | Alzheimer’s disease, DM,HT | Ceftibuten | 10 | 130 |
| 25 (610) | M/89 | Symptomatic (1) | Dementia | Amoxicillin/clavulanate | 49 | 8 |
| 26 (627) | M/62 | Colonization | IHD | Cefuroxime | 8 | NA |
| 27 (92) | F/90 | Symptomatic (1) | HT | Amoxicillin/clavulanate | 18 | 309 |
| 28 (113) | M/85 | Colonization | Dementia | Nil | 17 | 47 |
| 29 (129) | F/80 | Symptomatic (1) | CRF, DM, HT | Amoxicillin/clavulanate | 376 | NA |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CA, carcinoma; CHF, congestive heart failure; CRF, chronic renal failure; DM, diabetes mellitus; HT, hypertension; IHD, ischemic heart disease; MDS, myelodysplastic syndrome; NA, not applicable; NPC, nasopharyngeal carcinoma; Tx, transplant
aThe disease score is defined as previously described [26]. Briefly, two points were given to patients with endoscopic confirmation of pseudomembranous colitis or those requiring intensive care support. One point each was given for age >60 years, temperature >38.3°C, albumin level <2.5 mg/dL, or peripheral WBC count>15,000 cells/mm3 within 48 h of symptom onset. Patients with two points were considered to have severe C. difficile-associated diarrhea (CDAD). Otherwise, the patient was stratified as infection
bCase was defined as healthcare-associated infection, as the symptoms onset was within 4 weeks after discharge from the hospital